Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biora Therapeutics, Inc. - Common Stock
(NQ:
BIOR
)
0.6677
+0.0127 (+1.94%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biora Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
October 05, 2023
Autonomous next-gen device exceeded performance targets in three recent preclinical studies
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
September 25, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
September 19, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
September 05, 2023
Confirmation of autonomous device function enables progress to testing of pharma collaborators’ molecules
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
August 03, 2023
Intellectual property relates to key features of the company’s liquid jet injection technology
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
July 27, 2023
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
July 17, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
July 05, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
June 28, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
June 26, 2023
An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 13, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
June 08, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 15, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
May 08, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
May 01, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
April 20, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
March 30, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
March 23, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
February 23, 2023
Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company’s current target
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
February 16, 2023
Average bioavailability greater than 50% with high consistency observed in animal study
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
January 19, 2023
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
January 09, 2023
Company is on track to move into the clinic with its lead targeted therapeutics program
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Reverse Stock Split
December 30, 2022
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
December 08, 2022
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
November 29, 2022
Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
November 07, 2022
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.